PMID- 29150631
OWN - NLM
STAT- MEDLINE
DCOM- 20190709
LR  - 20190709
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 7
IP  - 1
DP  - 2017 Nov 17
TI  - Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in 
      Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis.
PG  - 15795
LID - 10.1038/s41598-017-16101-1 [doi]
LID - 15795
AB  - Patients with type 2 diabetes mellitus (T2DM) experience many cardiovascular 
      complications. Several studies have demonstrated the cardioprotective effects of 
      incretin-based therapies; however, there are few studies on the effects of 
      long-term incretin-based therapies on cardiovascular events. Therefore, the 
      present study conducted a systematic review and network meta-analysis to evaluate 
      the effects of long-term incretin-based therapies on ischaemic diseases. We 
      searched PubMed, CENTRAL, and Clinicaltrial.gov to retrieve randomised control 
      trials reported until December 2016 and enrolled only RCTs with more than a 
      1-year follow-up. The network meta-analysis was performed using R Software with a 
      GeMTC package. A total of 40 trials were included. Dipeptidyl peptidase 4 
      inhibitors and glucagon-like peptide-1 agonists were associated with a lower risk 
      of myocardial infarction (MI) than were sulfonylureas (odds ratio [95% credible 
      interval] 0.41 [0.24-0.71] and 0.48 [0.27-0.91], respectively). These results 
      suggested that patients with T2DM receiving long-term incretin-based therapies 
      have a lower risk of MI than do those receiving sulfonylurea-based therapy. These 
      findings highlight the risks of cardiovascular events in patients who receive 
      long-term incretin-based therapies, and may provide evidence for the selection of 
      antidiabetic therapy in the future.
FAU - Chou, Che-Yi
AU  - Chou CY
AUID- ORCID: 0000-0003-4029-9097
AD  - Kidney Institute and Division of Nephrology, Department of Internal Medicine, 
      China Medical University Hospital, Taichung, 40447, Taiwan.
FAU - Chang, Ying-Tzu
AU  - Chang YT
AD  - Department of Pharmacy, College of Pharmacy, China Medical University, Taichung, 
      Taiwan R.O.C.
FAU - Yang, Jia-Lian
AU  - Yang JL
AD  - Department of Pharmacy, College of Pharmacy, China Medical University, Taichung, 
      Taiwan R.O.C.
FAU - Wang, Jiun-Yi
AU  - Wang JY
AD  - Department of Healthcare Administration, Asia University, Taichung, Taiwan R.O.C.
FAU - Lee, Tsui-Er
AU  - Lee TE
AD  - Office of Physical Education, Asia University, Taichung, Taiwan R.O.C.
FAU - Wang, Ruey-Yun
AU  - Wang RY
AD  - Department of Public Health, China Medical University, Taichung, Taiwan R.O.C.
FAU - Hung, Chin-Chuan
AU  - Hung CC
AD  - Department of Pharmacy, College of Pharmacy, China Medical University, Taichung, 
      Taiwan R.O.C.. cc0206hung@gmail.com.
AD  - Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan 
      R.O.C.. cc0206hung@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20171117
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Aged
MH  - Diabetes Mellitus, Type 2/*complications/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/pharmacology/therapeutic use
MH  - Female
MH  - Glucagon-Like Peptide 1/agonists/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - Incretins/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*complications/*drug therapy
MH  - Publication Bias
MH  - Risk Factors
MH  - Time Factors
PMC - PMC5694013
COIS- The authors declare that they have no competing interests.
EDAT- 2017/11/19 06:00
MHDA- 2019/07/10 06:00
PMCR- 2017/11/17
CRDT- 2017/11/19 06:00
PHST- 2017/04/06 00:00 [received]
PHST- 2017/11/08 00:00 [accepted]
PHST- 2017/11/19 06:00 [entrez]
PHST- 2017/11/19 06:00 [pubmed]
PHST- 2019/07/10 06:00 [medline]
PHST- 2017/11/17 00:00 [pmc-release]
AID - 10.1038/s41598-017-16101-1 [pii]
AID - 16101 [pii]
AID - 10.1038/s41598-017-16101-1 [doi]
PST - epublish
SO  - Sci Rep. 2017 Nov 17;7(1):15795. doi: 10.1038/s41598-017-16101-1.